Machine Learning Platform
for Translational Medicine

Providing value to biopharma and diagnostic companies
at different stages of development, suporting your efforts
from bench to bedside.

image01
Analysing your data streams to extract knowledge and insight

SimplicityBio’s machine learning platform - BOSS - analyses your biological, clinical, digital data streams to extract knowledge and insight that can lead to disease mechanism understanding, drug target discovery, biomarker identification, patient stratification, and drug repositioning.
Our unique multi-biomarker agnostic approach discovers novel combinations of new (or validated) biomarkers from structured data provided by our clients. The resulting models are also human interpretable and robust.
Clients have secure access to BOSS, in order to investigate the raw results, query models, and also analyse their own data.

Robustness throughout development and different cohorts

SimplicityBio’s unbiased approach supports early target identification (deciphering), to pre-clinical (e.g. toxicity, efficacy, bridging biomarkers) and clinical phases (drug repositioning, patient selection or stratification, diagnostic, prognostic). BOSS provides unprecedented support for technological switch, as you move from exploratory discovery (e.g. NGS) to a more focused validation and commercialization (e.g. qPCR).

Communicate actionable results with all stakeholders

Unlike other solutions, BOSS generates models which are white-box by design. This allows multidisciplinary teams to review models and clearly articulate the biological meaning to all stakeholders: bioinformaticians, biologists, clinicians, key opinion leaders, management and regulatory agents. Models are a combination of markers and rules, the latter being a concept from fuzzy logic, a core component of our machine learning pipeline.

Enhance your efforts from R&D to Market

From as early as target identification to pre-clinical and clinical phases, BOSS generates performant and robust multi-biomarker models and validates them on follow-up cohorts (usually bigger and more diverse). As you move closer to having a test, BOSS helps fine-tune the models (without changing the biomarkers), or keep their performance as you switch to another platform (e.g. NGS to qPCR). After the final model has been selected, BOSS allows you to execute it and generate predictions for new patients. Data can be securely saved, for future performance improvements.

Our Clients


"I have no hesitation in highly recommending SimplicityBio as a great partner. They have been with us in every step of our project over the last two years, from discovery of candidate biomarker signatures all the way through to their validation. Their unique platform delivered robust signatures that kept performing even when switching from plasma to serum and before being optimised. They have helped us extract the best from our data, exploring it fully in both the technical and commercial areas. This gave us the outcomes we needed and the confidence to raise funds and move forward. Without SimplicityBio's technology (and team support) it would not have been possible. Their responsiveness and commitment to understand our needs makes them a partner of choice"

Dr Brad Walsh
CEO | Mi)nomic International Ltd
Adjunct Professor | Macquarie University


"We were very enthusiastic about working together and discovering new original and non-traditional methods to analyze our data. In case we want to implement this type of approach in any other study, we won’t hesitate to come back to SimplicityBio."

Sophie Blein Ph.D
Biostatistics/Bioinformatics | bioMérieux
Medical Diagnostics Discovery Department | MD3

News

Peer-Reviewed Article On Early Diagnosis Of Parkinson's

Early diagnosis of Parkinson's using panels of either miRNAs-only or a combination of miRNAs and proteins, from CSF.

Artificial Intelligence And Big Data In Pharma

SimplicityBio was invited to give a talk focused on "AI in personalized medicine", as well as panelist.

Poster, MiCheck-01 prospective trial results at ASCO GU Cancers Symposium 2018

SimplicityBio’s customer Minomic presents the MiCheck assay results. The 350-patient study highlights the test’s performance in differentiating Aggressive from Non-Aggressive Prostate Cancer. Algorithm development are ongoing.

SimplicityBio is Awarded the CTI Start-Up Label

SimplicityBio's CTI Start-Up journey was crowned by the CTI Label, a seal of quality, achievement, and a sign of credibility and readiness for sustainable growth. The label is awarded after a technical, IP and financial assessment of SimplicityBio and a final presentation to seasoned entrepreneurs.